Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.


0.5 stars

308 Reads | 0 Comments | 0 People call this a favourite


  • T.PLI:Insider buy 1 million shares

    165 Reads | 0 Comments | 5 days ago

      Filing Date Transaction Date Insider Name Ownership Type Securities Nature of transaction Volume or Value Price Jun 29/15 Jun 29/15 Clulow, Kurt Stefan Victor Control or Direction Common Shares 10 - Acquisition in the public market 114,750 ...

  • T.PLI:NR:PBI-4050 Anti-Fibrotic Effect Confirmed on Human Kidney Cells

    73 Reads | 0 Comments | June 1, 2015

    ProMetic's PBI-4050 Anti-Fibrotic Effect Confirmed on Human Kidney Cells   ProMetic Life Sciences Inc.8 hours ago             ...

  • T.PLI:Good post on sp valuation by Fdesloges..

    223 Reads | 1 Comment | May 28, 2015

    . A Valuation Update. Ok it's been a while since my last valuation update and there's been a lot of very nice material info that have slipped thru NRs and presentation alike. So here's my understanding of what's to come.   Let's start with the Winnipeg plasma plant NR.   Last year, we had the Laval 150kl capacity available now + the Taiwan 300kl capacity...

  • T.PLI:new price target! 3.25$.

    227 Reads | 1 Comment | May 8, 2015

    Canaccord: Buy rating and $3.25 target price for ProMetic According to Canaccord Genuity:   ProMetic Life Sciences Inc.   RATING: BUY (unchanged)   PRICE TARGET: C$3.25↑ from C$3.00   Raising Target Price   Identifying yet another opportunity: ProMetic adds C1-INH to its pipeline  ...

  • T.PLI:Closing of $50 M Bought Deal Offering of Common Shares

    260 Reads | 0 Comments | May 6, 2015

    some shares still available below that price of 2.60$ at market;) ProMetic Announces Closing of $50 M Bought Deal Offering of Common Shares LAVAL, QUEBEC--(Marketwired - May 6, 2015) - ProMetic Life Sciences Inc. (TSX:PLI)(OTCQX:PFSCF), ("ProMetic" or the "Corporation") closed today its previously announced bought deal public offering of common shares in the capital of...

  • T.PLI:IR comments on the 50M$ financing...

    253 Reads | 1 Comment | April 17, 2015

    Here is Fred's answerers to a couple of questions I had about the recent financing announcement. Hi Doug, To the contrary, things are going on very well at PLI. The financing was rendered necessary for a few reasons:   1- We needed to have a balance sheet and a cash position that is more in line with our market cap, compared to our peers and with industry standards for a...

  • T.PLI:BNN: we're top pick #1

    222 Reads | 0 Comments | March 19, 2015

    TOP Pick Today

  • T.PLI:article:PLI celebrates diabetic kidney disease drug milestone

    253 Reads | 1 Comment | September 3, 2014

    ProMetic Life Sciences (T.PLI) celebrates diabetic kidney disease (DKD) drug milestone   ProMetic Life Sciences (TSX: PLI, Stock Forum) celebrated another important milestone in the regulatory journey for its anti-fibrotic, lead drug candidate, PBI-4050, when the company announced today that it had a successful Pre-Investigational New Drug (“Pre-IND”) meeting with the...